BioCardia (STU:6JU0) Short Interest


STU:6JU0 BioCardia Inc STU:6JU0
17 GF Score
Price €0.27
GF Value €0.01
! 1 Warning Sign
View Full Analysis

What is BioCardia Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:6JU0 vs GRTX, CELU, KTTA: Short Interest Comparison

For the Biotechnology subindustry, BioCardia's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCardia Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Short Interest distribution charts can be found below:

* The bar in red indicates where BioCardia's Short Interest falls into.


STU:6JU0
17GF Score
BioCardia Inc STU:6JU0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioCardia (STU:6JU0) Overvalued in 2026?

Based on GuruFocus' analysis, BioCardia stock appears to be overvalued. The current stock price of €0.27 is trading 2600% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6JU0:

  • Short Interest:
  • GF Value™: €0.01 vs. price of €0.27 (2600% above fair value)
  • GF Score™: 17/100 with 1 warning sign

No single metric tells the full story. See the STU:6JU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCardia Business Description

Other Exchanges BCDA:USA
Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
17GF Score

Get the complete analysis for STU:6JU0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.01
GF Value